Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
about
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatasesIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activityModulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs.Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Computational modeling in melanoma for novel drug discovery.Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.Akt Signaling Is Sustained by a CD44 Splice Isoform-Mediated Positive Feedback Loop.Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt.Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.Network dynamics-based cancer panel stratification for systemic prediction of anticancer drug response.A central role for PI3K-AKT signaling pathway in linking SAMHD1-deficiency to the type I interferon signature.Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.Protein Kinase Targets in Breast Cancer.Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.Alphavirus-induced hyperactivation of PI3K/AKT directs pro-viral metabolic changes.Magnesium sulfate protects the heart against carbon monoxide-induced cardiotoxicity in rats.Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens.Triangle of AKT2, miRNA, and Tumorigenesis in Different Cancers.PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies.Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing.A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.Concurrent interactome and metabolome analysis reveals role of AKT1 in central carbon metabolism.In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.Anticancer Activity of Euplotin C, Isolated from the Marine Ciliate Euplotes crassus, Against Human Melanoma Cells.The Flavonoid Jaceosidin from Artemisia princeps Induces Apoptotic Cell Death and Inhibits the Akt Pathway in Oral Cancer Cells.Inhibition of ERK1/2 or AKT Activity Equally Enhances Radiation Sensitization in B16F10 Cells.PNUTS at the crossroads of tumorigenesis and metastasis formation.The Akt pathway in oncology therapy and beyond (Review)Phosphorylation-Dependent Inhibition of Akt1
P2860
Q29248612-71184652-D00D-45DA-80FD-80EECAA47CA2Q33601377-33B86842-D40B-4339-9B10-0BC6A41DAF66Q36262959-954D8731-2700-485C-A06F-8ABFA796CF28Q37618816-C3ABA550-7E2C-45C1-8346-965946726D6BQ37706287-5BA6A09E-D8DD-4BDA-B10F-EA5ABACE4748Q37718697-4107EB5C-FA9D-4DAD-85DB-1326301008E3Q37729599-8F3C8215-1E41-4A5B-B774-1598118C0F18Q38694488-15F38560-8DDC-45E2-A1A0-CDC33FA43035Q38798578-B892E976-5FA6-45BF-8A79-D7985898610FQ41093512-A597431A-3167-4227-B83D-3BFE65758774Q41546742-73A8698E-4672-4768-8040-E519B817922CQ41718303-069577A2-F5BF-44BB-901D-F4289B5AF2ABQ44551180-BD42271E-45E1-449F-AC1C-12CDC5FFB230Q47155414-72F95C80-7BBB-4192-BF1E-AB21FCA7020DQ47192927-DE0BBC91-2CC6-4EF4-A264-73BCFA8C1A50Q47212637-FC460595-7E0E-441D-B940-CEF6BE4CACD9Q47351355-85BEC394-CD22-449B-B83D-4695C29E4FEEQ47428473-5E7B7EE5-04E5-4E9A-9B7A-DACE62B81902Q47548291-5C54D602-2A5D-492E-9DA3-AA0906CB59D3Q47640638-7305677C-659B-403D-9918-07EC37E36E02Q48100849-183C90B7-5F2F-432E-8457-1EDDDD9899A6Q49333350-D6AFCB6B-6978-4522-A29D-2DCBFA162FE9Q49887901-50D1367A-60FA-49CC-94E9-45F82A80250AQ50097295-C158B3DD-90B1-4650-A9A4-1167F8BBC8DDQ50119043-0226E652-80D9-4478-8F8B-3A709EE3F0C1Q51483438-0559F57B-6ED5-456A-961F-9A7B0C515737Q51736090-FF8CE802-9050-4A52-91AB-DA500381BCADQ52673571-9F247614-48E5-436A-8505-7D49EF7B5DB2Q52714549-EF4E6A7F-B8D0-44E4-B415-810C3AC657BDQ52726054-764DFF7C-9048-4C4F-8674-2DD1E63CAF1DQ55001065-F98C992D-BDB6-403C-AEEA-DE96A683EFFBQ55131025-B08D1142-8A43-4C41-970F-EF35AF3AB096Q55223067-01D05A0E-5DB4-42C4-B69D-EC4D70BC2BFCQ55395126-E6336E23-2546-4A0B-A4A3-84660C0A2268Q55438895-A2E3A4F0-7E0E-4ECF-8F02-BA5633A407B1Q58555910-1DC11A6F-33F0-4A9C-BC4B-67D7297AD7CAQ58758462-1674B192-1BCC-435B-BEDA-BD6EB31C166B
P2860
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@ast
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@en
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@nl
type
label
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@ast
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@en
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@nl
prefLabel
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@ast
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@en
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@nl
P2093
P2860
P50
P921
P356
P1476
Akt inhibitors in cancer treat ...... overy to clinical use (Review)
@en
P2093
Massimo Libra
Petras Juzenas
P2860
P304
P356
10.3892/IJO.2015.3306
P407
P50
P5008
P577
2016-03-01T00:00:00Z